Publications

Science Founded on Unique Insights, Powered by Groundbreaking Research

A collection of research papers, scientific publications and presentations relevant to our platform, processes and products.
Publications
Topic
Indication
Therapy
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 (COVID-19) in Immunocompromised Patients
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting
Posoleucel, an Allogeneic, Off-the-Shelf Multi-Virus Specific T Cell Therapy, for Severe, Drug -Refractory Viral Infections in Pediatric Patients Following HCT: Results from a Phase 2 Trial
Allogeneic, Off-the-Shelf, SARS-CoV-2-Specific T Cells (ALVR109) for the Treatment of COVID-19 in High Risk Patients
Longitudinal Analysis of the Evolution of Cellular Immunity to SARS-CoV-2 Induced by Infection and Vaccination
Clinical Course of a Kidney Transplant Recipient with BK Polyomavirus Administered Posoleucel Multivirus Specific T Cells
Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety, Tolerability and Efficacy in a Phase 2 Trial
Exploring Hepatitis B Virus as an Immunotherapeutic Target for Clinical Trials of Adoptively Transferred T Cells
Clinical and Economic Burden of Multiple dsDNA Viral Infections After Allogeneic Hematopoietic Cell Transplantation
Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety and Tolerability in a Phase 2 Trial
Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report
Early Clinical Experience with ALVR109, a Partially Hla-matched Sars-cov-2 Specific T-cell Therapy, in Immunocompromised Patients with COVID-19
Economic and Clinical Burden Associated with Respiratory Viral Infections After Allogeneic Hematopoietic Cell Transplant
Multivirus-Specific T-Cell Therapy with Posoleucel (ALVR105) for Refractory Disseminated Adenovirus Infection after Allogeneic HCT
Successful Treatment with ALVR105 for Disseminated Adenovirus Infection in an Infant after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Results from an Open-Label Cohort of a Phase 2 Trial
Posoleucel, Multivirus-Specific T-Cell (VST) Therapy, for Prevention of Clinically Significant Viral Infections in Allogeneic Transplant Recipients: Persistence of VSTs in an Open-Label Phase 2 Trial
Posoleucel for the Prevention of Clinically Significant Infections in High-Risk Allogeneic Hematopoietic Cell Transplant Recipients: Design of a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
Posoleucel for Adenovirus Infection in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: Design of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
ALVR109, an Off-the-Shelf Partially HLA Matched SARS-CoV-2–Specific T Cell Therapy, to Treat Refractory Severe COVID-19 Pneumonia in a Heart Transplant Patient: Case Report
Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial
Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells Demonstrate Reactivity Against Emerging Variant Strains
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of VIRALYM-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis After Allogeneic Haematopoietic Stem Cell Transplantation
Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19
Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Pediatric and Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
Economic Burden and Health Resource Utilization Associated with Dsdna Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Allogeneic, Off-the-Shelf Multi-Virus Specific T-Lymphocytes for the Treatment of Virus-Associated Hemorrhagic Cystitis in the Post-HSCT Setting
Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States
Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19
Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study
Health Resource Utilization and Costs Associated with Multi-Virus infection after Allogeneic Hematopoietic Cell Transplantation
Economic and Clinical Burden of Respiratory Virus infections in Allogeneic Hematopoietic Cell Transplantation Recipients
"Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients
Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections
Infusion of Cytotoxic T Lymphocytes for the Treatment of Viral Infections in Hematopoetic Stem Cell Transplant Patients
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation
Antiviral T-cell Therapy
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Virus-specific T Cell Therapy Platform
Virus-specific T Cell Therapy Platform
Clinical Data
Clinical Data
Preclinical Data
Preclinical Data
Health Economics / Outcomes Research Data
Health Economics / Outcomes Research Data
Viral Treatments - SOT
Viral Treatments - SOT
Hepatitis B Treatment/Cure
Hepatitis B Treatment/Cure
COVID-19 Treatment
COVID-19 Treatment
Respiratory Virus Treatment
Respiratory Virus Treatment
BK Virus Nephropathy – Kidney Transplant
BK Virus Nephropathy – Kidney Transplant
Multi-virus Prevention
Multi-virus Prevention
Viral Treatments - HCT
Viral Treatments - HCT
Hemorrhagic Cystitis Treatment
Hemorrhagic Cystitis Treatment
Adenovirus Treatment
Adenovirus Treatment
ALVR109
ALVR109
ALVR107
ALVR107
ALVR106
ALVR106
Posoleucel (ALVR105, Viralym-M)
Posoleucel (ALVR105, Viralym-M)
No results found.
Please try different keywords.
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?